{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:32:14Z","timestamp":1787758334208,"version":"build-2784847793"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      For preparing the optimal condition in transcervical resection (TCR) surgery, gonadotropin-releasing hormone (GnRH) agonist has been utilized. Recently, an oral GnRH antagonist (relugolix) is available and acts directly on GnRH receptor, avoiding flare up and reducing blood E2 levels rapidly. We retrospectively compared the oral GnRH antagonist (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 14) effect to that of subcutaneous GnRH agonist (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 19) for the pretreatment of endometrium in TCR myomectomy. Endometrial thickening was determined by intraoperative videos. The color tone of the endometrium in the normal part was assessed by digital image processing. The median duration of the first GnRH agonist injection and the surgery was 67 days (21\u2013136 days), which is significantly longer than that of the oral GnRH antagonist group, 18.5 days (7\u2013157 days\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01). Both the GnRH agonist and antagonist groups did not exhibit prominence in the endometrium. The GnRH antagonist group showed the same degree of whiteness in the normal endometrium as the GnRH agonist group. The oral GnRH antagonist administration could rapidly atrophy the endometrium and create an optimal surgical field for TCR in a short period.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/gmit.gmit_9_22","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T02:28:44Z","timestamp":1667788124000},"page":"238-241","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Has the Same Effect as Gonadotropin-Releasing Hormone Agonist Injections in Terms of Preparation for Transcervical Resection Myomectomy"],"prefix":"10.4103","volume":"11","author":[{"given":"Mika","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Hiraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouta","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Iwahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Furue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Nishijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahito","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruko","family":"Iwase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Tagaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuya","family":"Unno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20240830","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1093\/humrep\/15.9.1989","article-title":"Is endometrial pre-treatment of value in improving the outcome of transcervical resection of the endometrium?","volume":"15","author":"Rai","year":"2000","journal-title":"Hum Reprod"},{"key":"R2-9-20240830","first-page":"CD010241","article-title":"Pre-operative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding","volume":"11","author":"Tan","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"R3-9-20240830","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4103\/GMIT.GMIT_88_20","article-title":"Comparison of bipolar ball endometrial ablation and transcervical resection of the endometrium in the treatment of heavy menstrual bleeding: A randomized clinical trial","volume":"10","author":"Subbaiah","year":"2021","journal-title":"Gynecol Minim Invasive Ther"},{"key":"R4-9-20240830","first-page":"CD001124","article-title":"Pre-operative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding","volume":"3","author":"Sowter","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"R5-9-20240830","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0015-0282(00)01767-2","article-title":"Goserelin acetate (Zoladex) plus endometrial ablation for dysfunctional uterine bleeding: A 3-year follow-up evaluation","volume":"75","author":"Donnez","year":"2001","journal-title":"Fertil Steril"},{"key":"R6-9-20240830","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.fertnstert.2019.07.013","article-title":"Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: A randomized, placebo-controlled, phase 3 study in Japanese women","volume":"112","author":"Osuga","year":"2019","journal-title":"Fertil Steril"},{"key":"R7-9-20240830","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/AOG.0000000000003141","article-title":"Oral gonadotropin-releasing hormone antagonist relugolix compared with leuprorelin injections for uterine leiomyomas: A randomized controlled trial","volume":"133","author":"Osuga","year":"2019","journal-title":"Obstet Gynecol"}],"container-title":["Gynecology and Minimally Invasive Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/gmit.gmit_9_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:13:07Z","timestamp":1787757187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/gmit.gmit_9_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":7,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/gmit.gmit_9_22","relation":{},"ISSN":["2213-3070"],"issn-type":[{"value":"2213-3070","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}